Diagnosis and Management of Waldenstrom's Macroglobulinemia

American Society of Clinical Oncology (ASCO) - Tập 23 Số 7 - Trang 1564-1577 - 2005
Meletios Α. Dimopoulos1, Robert A. Kyle1, Athanasios K. Anagnostopoulos1, Steven P. Treon1
1From the Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; Division of Hematology, Mayo Clinic, Rochester, NY; Department of Hematology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Tóm tắt

Purpose To review the diagnostic criteria, prognostic factors, response criteria, and treatment options of patients with Waldenstrom's macroglobulinemia (WM). Methods A review of published reports was facilitated by the use of a MEDLINE computer search and by manual search of the Index Medicus. Results WM should be regarded as a distinct clinicopathologic entity and confined to those patients with lymphoplasmacytoid lymphoma who have demonstrable serum immunoglobulin M monoclonal protein. Treatment decisions should rely on specific clinical and laboratory criteria. Initiation of therapy should not be based on serum monoclonal protein levels per se. The three main choices for systemic primary treatment of symptomatic patients with WM include alkylating agents (chlorambucil), nucleoside analogs (fludarabine and cladribine), and the monoclonal antibody rituximab. There are no data from prospective randomized studies to recommend the use of one first-line agent over another, although consideration of a patient's candidacy for autologous stem-cell transplantation (ASCT) should be taken into account to avoid stem cell–damaging agents. There are preliminary data to suggest that combinations of nucleoside analogs and alkylating agents with or without rituximab may improve response rates at the expense of higher toxicity. Conclusion WM is a distinct low-grade lymphoproliferative disorder. When therapy is indicated, alkylating agents, nucleoside analogs, and rituximab are reasonable choices. Several factors, including the presence of cytopenias, need for rapid disease control, candidacy for ASCT, age, and comorbidities, should be taken into consideration when choosing the most appropriate primary treatment.

Từ khóa


Tài liệu tham khảo

Waldenstrom J: Incipient myelomatosis or “essential” hyperglobulinemia with fibrinogenopenia: A new syndrome? Acta Med Scand 117:216,1944-222,

10.1053/sonc.2003.50082

10.1182/blood.V84.5.1361.1361

10.1200/JCO.1999.17.12.3835

10.1053/sonc.2003.50073

10.1053/sonc.2003.50074

10.1200/JCO.2000.18.1.214

10.1182/blood-2003-03-0801

10.1016/S0025-6196(12)65225-2

10.1182/blood.V83.6.1452.1452

Fudenberg HH, Virella G: Multiple myeloma and Waldenstrom macroglobulinemia: Unusual presentations. Semin Hematol 17:63,1980-79,

10.1097/00000478-200308000-00007

10.1097/00007611-199807000-00017

10.1093/ndt/12.6.1256

10.1016/S0190-9622(99)70434-2

10.1016/0039-6257(81)90065-5

Civit T, Coulbois S, Baylac F, et al: Waldenstrom's macroglobulinemia and cerebral lymphoplasmacytic proliferation: Bing and Neel syndrome—Apropos of a new case. Neurochirurgie 43:245,1997-249,

10.1055/s-2007-994921

Farhangi M, Merlini G: The clinical implications of monoclonal immunoglobulins. Semin Oncol 13:366,1986-379,

10.1056/NEJM199001183220308

10.1200/JCO.1993.11.5.914

10.1053/sonc.2003.50060

10.1007/BF02982553

10.1056/NEJM199805283382207

10.1111/j.1750-3639.2001.tb00407.x

10.1016/0002-9343(82)90852-X

Lindstrom FD, Hed J, Enestrom S: Renal pathology of Waldenstrom's macroglobulinemia with monoclonal antiglomerular antibodies and nephritic syndrome. Clin Exp Immunol 41:196,1980-204,

10.1016/j.ophtha.2003.05.036

10.1053/sonc.2003.50038

10.1053/sonc.2003.50051

10.1053/sonc.2003.50056

10.1182/blood.V83.10.2939.2939

Morel P, Monconduit M, Jacomy D, et al: Prognostic factors in Waldenstrom macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 96:852,2000-858,

10.1046/j.1365-2141.2001.03144.x

10.1309/4LCN-JMPG-5U71-UWQB

10.1093/annonc/mdg334

10.1053/sonc.2003.50050

10.1053/sonc.2003.50064

10.1080/10428190410001687512

10.1053/sonc.2003.50037

10.1046/j.1365-2141.2000.01918.x

10.1182/blood.V98.9.2640

10.1046/j.1526-0968.2001.00301.x

10.1055/s-2003-44560

Buskard NA, Galton DAG, Goldman JM, et al: Plasma exchange in the long-term treatment of Waldenstrom's macroglobulinemia. Can Med Assoc J 117:135,1977-137,

10.1056/NEJM199111213252105

10.1002/(SICI)1097-4598(200002)23:2<150::AID-MUS2>3.0.CO;2-G

10.1007/s11864-000-0055-4

10.1159/000064747

10.1200/JCO.1999.17.2.546

10.1200/JCO.1994.12.12.2694

10.1007/s002770050247

10.1111/j.1600-0609.1999.tb01848.x

10.1046/j.1365-2141.1999.1331f.x

Hampshire A, Saven A: Update of bolus administration of cladribine in the treatment of Waldenstrom's macroglobulinemia. Blood 102:402a,2003, (abstr)

10.1016/0002-9343(93)90231-D

10.1200/JCO.1998.16.6.2060

10.1093/oxfordjournals.annonc.a059040

10.1046/j.1365-2141.1997.3923206.x

10.1093/oxfordjournals.annonc.a058811

Case DC, Ervin TJ, Boyd MA: Long term results and disease characteristics of patients with Waldenstrom's macroglobulinemia treated with the M-2 protocol. Blood 82:561a,1993, (abstr 2230)

10.1111/j.1365-2796.1989.tb01422.x

10.1053/sonc.2003.50070

10.1080/1042819031000077025

10.1046/j.1365-2141.1999.01461.x

10.1038/sj.bmt.1703041

10.1053/sonc.2003.50048

10.1038/sj.bmt.1701633

Maloney DG, Sandmaier BM, Maris M, et al: Allogeneic hematopoietic cell transplantation for refractory Waldenstrom's macroglobulinemia: Replacing high-dose cytotoxic therapy with graft-versus-tumor effect. Blood 102:472b,2003, (abstr)

10.1200/JCO.1998.16.8.2825

10.1053/sonc.2002.33539

10.1200/JCO.1997.15.4.1567

10.1053/sonc.2003.50047

Treon SP, Shima Y, Preffer FI, et al: Treatment of plasma cell dyscrasias with antibody-mediated immunotherapy. Semin Oncol 26:97,1999-106, (suppl 14)

10.1023/A:1008350208019

Weber DM, Gavino M, Huh Y, et al: Phenotypic and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia. Blood 94:125a,1999, (abstr 551)

10.1200/JCO.2000.18.2.317

10.1097/00002371-200105000-00012

10.1200/JCO.2002.09.039

10.1080/10428190410001723287

10.1093/annonc/mdi022

10.1080/10428190410001714043

Ghobrial IM, Fonseca R, Greipp PR, et al: The initial “flare” of IgM level after rituximab therapy in patients diagnosed with Waldenstrom Macroglobulinemia: An Eastern Cooperative Oncology Group Study. Blood 102:448a,2003, (abstr)

10.1093/annonc/mdh403

Treon SP, Hansen M, Branagan AR, et al: Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical responses to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol (in press)

10.1212/WNL.52.8.1701

10.1182/blood-2003-10-3597

10.1182/blood-2002-10-3162

10.1182/blood-2002-09-2856

Owen RG, Rawstron AC, Osterborg A, et al: Activity of alemtuzumab in relapsed/refractory Waldenstrom's macroglobulinemia. Blood 102:644a,2003, (abstr)

10.3109/10428199409049636

10.3109/10428199509107907

10.1182/blood.V81.5.1132.1132

10.1200/JCO.2001.19.16.3596

10.1053/sonc.2003.50044

10.1053/sonc.2003.50079

10.1053/sonc.2003.50065

Goy AG, Younes A, Mc Laughilin P, et al: A phase II study of proteasome inhibitor bortezomib in relapsed or refractory indolent or aggressive B-cell non-Hodgkin's lymphoma. Hematology J 5:S204,2004-S205, (suppl 2)

10.1053/sonc.2003.50041

10.1053/sonc.2003.50045

10.3816/CLM.2004.n.029

10.1053/sonc.2003.50058

10.1053/sonc.2003.50039

10.1080/10428190310001597946

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 23 Số 7

1564-1577

Thông tin tác giả